In November 2020, three in-vitro diagnostic-related companies, AVE Science & Technology Industry Co., Ltd , Assure Tech (Hangzhou) Co., Ltd, and Novogene, had the first launch of the sci-tech innovation board; Dynamiker Biotechnology (Tianjin) Co., Ltd.'s application for the sci-tech innovation board was accepted; Shanghai Rendu Biotechnology Co., Ltd. is filed with Shanghai Securities Regulatory Bureau and plans to be listed on the Science and Technology Innovation Board.

It is reported that the in-vitro diagnostic companies that have passed the Sci-Tech Innovation Board and submitted for registration are: YHLO, Liferiver, and HOB Biotech Group, and companies’ sci-tech innovation board succeeded include Beijing Chemclin Biotech Co., Ltd. and Hangzhou AllTest Biotech Co., Ltd..

It is expected that in the first quarter of 2021, the Science and Technology Innovation Board will usher in the climax of the listing of IVD companies!

November: One enterprise's application for science innovation board was accepted

On November 20, Dynamiker Biotechnology (Tianjin) Co., Ltd. 's application for listing on science innovation board was accepted.

Dynamiker Biotechnology(Tianjin)Co., Ltd is a comprehensive biomedical national high-tech enterprise, built by Dr. Zeqi Zhou from Harvard Medical School, who is rewarded as Biomedical Talent of Jing-Jin-Ji. Established in March 2014, Dynamiker is dedicated to R&D, production, clinical application and technical service of Invasive Fungal Disease (IFD) diagnosis. With the mission of building international renowned brand for early and rapid IVD products for IFD, Dynamiker has become the global leader in IFD diagnosis.

November: 3 companies' science and technology innovation board first launch meeting

On November 13, the 102nd review meeting of the Municipal Party Committee of the Science and Technology Innovation Board in 2020 approved the ipo of Aiwei Technology Co., LTD. (IPO).

AVE Science & Technology Industry Co., Ltd is a state-level high-tech enterprise founded in Mar.,2000 and locates in Changsha High-Tech Industrial Development Zone, specializes in researching, developing, manufacturing, marketing and technology service of newest medical treatment instrument, experiment instrument, remote medical diagnosis network, medical diagnostic reagents and is stretching to other wider area. Main products are biochemical analyzer, urine formed elements (urine sediments) analyzer with reagent, dejecta analyzer and multi-functional microscopy analyzer.

On November 11, the 101st review meeting of the Municipal Party Committee of the Science and Technology Innovation Board in 2020 approved Novogen to issue and list (initial release).

Novogen was established in 2011, focusing on pioneering the application of cutting-edge molecular biology technology and high-performance computing in life science research and human health. Novogen has always adhered to the accumulation and innovation of gene sequencing technology and its application fields. , Independently developed human EGFR, KRAS, BRAF, PIK3CA, ALK, ROS1 gene mutation detection kit (semiconductor sequencing method) and other gene sequencing medical equipment.

On November 3,Assure Tech (Hangzhou) Co., Ltd. was approved to go public (ipo) at the 94th review meeting of the Municipal Committee of Science and Technology Innovation Board in 2020.

Assure Tech (Hangzhou) Co., Ltd is established by senior experts of in-vitro diagnostics industry in 2008.As a high-tech biotechnology company, Assure Tech is specialized in Research & Development, production and sales of diagnostic reagents and biological materials. At present, the company has 6,000 square meters of R&D and manufacturing base, which contains the advanced level of colloidal gold diagnostic reagents production lines with annual production capacity of hundred millions of devices. Currently, Assure R&D team with more than 100 staff is setting up an extensive collaboration with the advanced domestic and foreign research institutions. 

November: 1 company accepted listing counseling

On November 4, Shanghai Rendu Biotechnology Co., Ltd. and CICC signed a listing guidance agreement, and it was filed with the Shanghai Securities Regulatory Bureau on the same day, and it was planned to be listed on the Science and Technology Innovation Board.

Shanghai Rendu Biotechnology Co., Ltd. was established in 2007. It is a domestic high-tech enterprise focusing on RNA molecular diagnostic technology and products. The company was jointly established by Chinese American scientists and domestic entrepreneurs. It is committed to the development and promotion of real-time fluorescence constant temperature amplification detection technology. Basic RNA molecular diagnostic products. Rendu Biology has a complete set of core technologies with independent intellectual property rights from diagnostic reagents to fully automatic supporting instrument development and production.